[PDF] Top 20 Evaluación de extractos vegetales como agentes antifúngicos para pinturas

... Since patients with elevated serum beta-2 microglobulin achieved lower CR rate and shorter PFS when treated with frontline chemoimmunotherapy (FCR), for this subgroup of high-risk patients a trial to ... See full document

... of rituximab infusions in the hospit- al outpatient setting was related to specific comorbidity or performance status, could not be ...possible patients with more severe disease were more likely to receive ... See full document

... 74 patients who completed treatment, 24% achieved CR, ...In patients with 17p del, 44% responded to cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), while 19% of ... See full document

... adding rituximab to fludarabine and cyclophosphamide scheme (FCR versus FC) for treatment-naïve and refractory/relapsed Ukrainian patients with chronic lymphocytic ...assess ... See full document

... CLL patients to receive six monthly cycles of FC or FCR, using the same dosing regimen as the MDACC ...of patients were Binet stage B or ...761 patients evaluable for response, 790 patients ... See full document

... Abstract: Chronic lymphocytic leukemia (CLL) is a hematologic malignancy derived from a clonal population of mature B-lymphocytes characterized by relatively low CD20 antigen ...of patients ... See full document

... to rituximab, an agent commonly used in the treatment of ...to treatment discontinuation in 7% of patients in the G-CLB arm compared to ,1% in the R-CLB ...these patients were ... See full document

... the patients received 400 mg venetoclax as con- tinuous therapy until disease progression, unacceptable side effects, or other reasons for discontinuation, like subsequent allogeneic stem-cell transplantation, ... See full document

... for rituximab, for which combination chemotherapy strategies have clearly improved disease responsiveness and advantage in survival outcome of patients with ... See full document

... 100 patients (90 B-CLL, 7 B-cell prolymphocytic leukemia, 3 Waldenström macroglobulinemia) using fl uorescence in situ hybridization (FISH) with a genomic p53 DNA ...100 patients exhibited a ... See full document

... Current treatment approaches in chronic lymphocytic leukemia include alkylating agents, purine nucleoside analogs and monoclonal antibodies ...current treatment options and novel ... See full document

... revolutionized treatment options and clinical outcomes in cancer pa- tients ...instance, rituximab, a first-in-class chimeric monoclonal antibody (MoAb) targeting CD 20 molecule, has had clear impact on ... See full document

... Next, we examined potential associations of epigenetic evolution regarding the EB and RC with particular bio- logical characteristics of the malignant clones. Consider- ing that the vast majority of cases (29/34, 85.2%) ... See full document

... than rituximab, which may lead to a longer duration of treatment response and could potentially result in a smaller dose being ...following treatment with ... See full document

... Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades ... See full document

... including rituximab (that binds to CD20 antigen on B-cell surface) are among the most effective treatment options 9,10 ...in patients treated with Rituximab, Fludarabine and Cyclophosphamide ... See full document

... CLL patients are represented by subjects older than 65 years, there is still a significant lack of treatment options for this ...overcome rituximab-based combination in terms of response quality and ... See full document

... antibody, rituximab, has considerably improved therapeutic outcome in B-cell chronic lymphocytic ...leukemia. Rituximab has limited clinical activity when used as a single ...pretreated ... See full document

... of patients with chronic lymphocytic leukemia (CLL) include an enhanced ability to make an accurate diagnosis and defi ne clinically meaningful prognostic groups, while improving outcome ... See full document

... Abstract: Chronic lymphocytic leukemia (CLL) is the most common adult ...current treatment paradigm involves the use of chemoimmunotherapy, when patients develop an indication for ...of ... See full document